The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy

Events
In collaboration with:

San Antonio Breast Cancer Symposium (SABCS) 2022 is approaching soon.

Florine de Groot from Leiden University Medical Center (LUMC) will present results of the NEOLBC randomized phase II trial that tailored neoadjuvant therapy in postmenopausal breast cancer patients during SABCS.

“The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy in selected patients with early luminal breast cancer”.

By using OncoSIGNal the authors observed that ER pathway activity decreased after two weeks upon letrozole treatment, but increased when switching to chemotherapy.

Date: Wednesday, December 7, 2022 | Poster Session 3 |
Poster# P3-07-07 | Hall 1

Contact us

E-Mail us oncosignal@innosignbio.com